FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average I	hurdon								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Simon Barry J.			2. Issuer Name and Ticker or Trading Symbol Cue Biopharma, Inc. [CUE]								(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) 21 ERIE STREET					3. Date of Earliest Transaction (Month/Day/Year) 01/02/2019									Office below	(give title		Other (s below)	pecify
(Street) CAMBRIDGE MA 02139					4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S		(Zip)															
		Tab	le I - Non-I	Deriva	tive	Sec	curities	s Ac	quired, D	isp	osed c	of, or Be	neficial	ly Owne	d 			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			Date	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)				Benefic Owned	es Form ally (D) of Following (I) (I		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership				
							Code	,	Amount	(A) o (D)	r Price	Reporte Transac (Instr. 3	ction(s)			Instr. 4)		
		Т	able II - De						uired, Dis , options					Owned				
Derivative Conversion Date Execuses Conversion (Month/Day/Year) if any		3A. Deemed Execution Da if any (Month/Day/Y	Code (Instr.			n of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Co	ode '	v	(A)	(D)	Date Exercisable	Ex Da	piration te	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$5.16	01/02/2019			A		9,600		01/02/2020	01	/02/2026	Common Stock	9,600	\$0.00	9,600		D	

Explanation of Responses:

Remarks:

/s/ Barry Simon by Mark Busch, as attorney-in-fact

01/03/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.